View : 367 Download: 0
A non-human primate model for stable chronic Parkinson's disease induced by MPTP administration based on individual behavioral quantification
- A non-human primate model for stable chronic Parkinson's disease induced by MPTP administration based on individual behavioral quantification
- Seo, Jincheol; Lee, Youngjeon; Kim, Born Sahn; Park, Junghyung; Yang, Sejung; Yoon, Hai-Jeon; Yoo, Jang; Park, Hyun Soo; Hong, Jung-Joo; Koo, Bon-Sang; Baek, Seung Ho; Jeon, Chang-Yeop; Huh, Jae-Won; Kim, Young-Hyun; Park, Sang Je; Won, Jinyoung; Ahn, Yu-Jin; Kim, Keonwoo; Jeong, Kang Jin; Kang, Philyong; Lee, Dong-Seok; Lim, Soo Mee; Jin, Yeung Bae; Lee, Sang-Rae
- Ewha Authors
- 임수미; 김범산; 윤혜전
- SCOPUS Author ID
- 임수미; 김범산; 윤혜전
- Issue Date
- Journal Title
- JOURNAL OF NEUROSCIENCE METHODS
- JOURNAL OF NEUROSCIENCE METHODS vol. 311, pp. 277 - 287
- Parkinson's disease; Non-human primate; MPTP; Global activity; Video-based tracking system
- ELSEVIER SCIENCE BV
- SCIE; SCOPUS
- Document Type
- Background: The guidelines for applying individual adjustments to macaques according to the severity of behavioral symptoms during 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment were provided to reproduce stable chronic Parkinsonism in a recent study (Potts et al., 2014). But, since there are insufficient guidelines regarding objective severity criteria of individual symptoms for adjustments of MPTP treatment, it is difficult to develop MPTP-induced chronic non-human primate (NHP) models with stable symptoms. New method: The individual adjustments of MPTP administration based on results of automatic quantification of global activity (GA) using a video-based tracking system were applied to develop MPTP-PD model. Low-dose (0.2 mg/kg) intramuscular injection was repeated continuously until GA was lower than 8% of baseline Parkinsonian behavior scores. The positron emission tomography imaging were used to follow the longitudinal course of Parkinson's disease (PD). Results: Significant reductions in GA and dopamine transporter activity, along with significant increases in Parkinsonian behavior scores were found from 4 to 48 weeks following the first administration. GA was correlated with the Parkinsonian behavior score. The dopamine transporter activity was correlated with GA and the Parkinsonian behavior score. However, it was not correlated with the total dose of MPTP. Damage of dopaminergic neuronal systems in the basal ganglia was confirmed by immunohistochemistry and Western blot. Comparison with existing method: This study reinforces previous guidelines regarding production of NHP models with stable Parkinsonian symptoms. Conclusions: This novel strategy of MPTP administration based on global activity evaluations provides an important conceptual advance for the development of chronic NHP Parkinsonian models.
- Appears in Collections:
- 의과대학 > 의학과 > Journal papers
- Files in This Item:
There are no files associated with this item.
- RIS (EndNote)
- XLS (Excel)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.